Magrolimab, the most advanced anti-CD47 antibody, resulted in a high response rate in hematological tumors (complete response (CR): 53% in untreated acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), 10% in relapsed/refractory AML/MDS179). Here, CD47 is linked to myelodysplastic syndrome.